Parkinson Mark Vincent sold $17K of ENSG

Parkinson Mark Vincent sold 100 shares of ENSIGN GROUP, INC (ENSG) at $168.12 on 2026-07-16 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Parkinson Mark Vincent
Published Jul 17, 2026, 8:20 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 17, 2026, 8:30 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ENSG
Neutral
high confidence
Mentioned
$ENSG
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ENSGNeutralLow
01

Why it matters

The disclosure provides transparency on insider selling activity but does not introduce new company fundamentals, guidance, or regulatory developments.

02

Market read

Traders may log the event for sentiment/positioning, but it is unlikely to drive price action given the planned nature and small dollar amount.

03

What to watch

Transaction size is small and does not indicate changes to operating performance; the key signal is whether there is a pattern of repeated sales beyond routine schedules.

Relevance 2/10Novelty 2/10Timing: Filed 2026-07-17 after-hours; reflects 2026-07-16 sale execution.

Background

This is an SEC Form 4 insider transaction disclosure for Ensign Group, Inc, reported as an open-market sale by a director.

Company-level read

Ticker impact

$ENSGNeutralHigh confidence
Context

Ensign Group director Mark Vincent sold 100 shares on 2026-07-16 at $168.12 under a pre-arranged 10b5-1 plan.

Expected impact

Low likelihood of a sustained price move; any reaction is likely muted and short-lived.

Evidence & confidence

The filing is a routine Form 4 open-market sale by a director, explicitly tied to a pre-arranged 10b5-1 plan, with modest transaction size ($16,812).

Market effects

No clear sector read-through from a single small 10b5-1 director sale.

None.

None.

Counterpoint

Even planned 10b5-1 sales can coincide with internal views on valuation, so traders may watch for follow-on sales or other insider activity.

Key entities

  • ENSG

    Ensign Group, Inc, the company whose director insider sale is disclosed.

  • Parkinson Mark Vincent

    Director who sold 100 shares on 2026-07-16 under a pre-arranged 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$DHCMedAI 8/10

DHC Q3 2026 slides: SHOP segment surges 50% despite earnings miss

Diversified Healthcare Trust (DHC) reported Q3 2026 results with a net loss of $0.21 per share, missing estimates. Shares fell 2.58% to $7.54. The SHOP segment saw a 50.4% NOI increase, while medical office and life science faced challenges. DHC raised same-property NOI guidance but lowered EBITDAre and FFO guidance due to management fees. The company has $260.7M in liquidity and a debt-to-EBITDAre ratio of 8.2x.

$ENSGHighAI 8/10

ENSG Q3 deep dive: organic growth and acquisitions drive occupancy and margin gains

Ensign Group (ENSG) reported Q3 revenue of $1.48 billion, missing estimates by 7.1%, but beat adjusted EBITDA expectations. The company raised full-year revenue guidance to $5.91 billion and GAAP EPS guidance to $7.98. Occupancy and skilled mix gains, along with acquisitions, drove growth. Management highlighted clinical model success and market expansion, including entry into Florida.

$ENSGMed

Truist raises Ensign Group stock price target to $210 on margins

Truist Securities raised its price target on The Ensign Group (NASDAQ:ENSG) to $210 from $207, citing strong Q3 results with revenue of $5.67B and EBITDA of $621.52M. The company beat EPS estimates and raised fiscal 2026 guidance. Truist noted positive occupancy trends, labor commentary, and M&A activity. ENSG's Q3 revenue missed estimates but earnings exceeded expectations.

$ENSGHighAI 8/10

The Ensign Group Q3 Earnings Call Highlights

Ensign Group (ENSG) reported Q3 earnings, raising its full-year 2026 adjusted earnings guidance to $7.94-$8.02 per share and revenue outlook to $5.89-$5.92 billion. The company added 22 operations, including nine in Florida, and discussed turnaround efforts for acquired facilities. Ensign had $337.6 million in cash and $512.3 million in cash flow from operations as of Sept. 30, with $1 billion in available capital.

$ENSGHighAI 8/10

Ensign Group Inc (ENSG) Q3 2026 Earnings Call Highlights: Raised Guidance, Strong

Ensign Group Inc (ENSG) raised its 2026 guidance, citing strong occupancy and skilled mix growth. Challenges include integrating 22 new operations, particularly in Florida and Texas, which may take over a year to contribute positively. The company faces risks from reimbursement variations and litigation environments. CEO Barry Port noted strong clinical outcomes and managed care partnerships. CFO Suzanne Snapper highlighted $1B in available funds for growth.

$ENSGMedAI 8/10

Nursing Home Giant Ensign Touts $1B for Future Investments, Census Momentum and New CMS Survey Performance in 3Q

Ensign Group (ENSG) reported Q3 earnings of $2.03 per share, up 23.8% YoY, and revenue of $1.48B, up 14.5%. CEO Barry Port highlighted strong occupancy, skilled-mix growth, and improved CMS survey performance. The company raised full-year 2026 guidance and announced 22 new acquisitions. Ensign has $1B in cash and credit capacity for future investments.